Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc for liver inflammation in HIV-associated fatty liver disease
ISRCTN15410818Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of maraviroc in metabolic dysfunction-associated steatohepatitis (MASH) and human immunodeficiency virus infection (HIV), sponsored by Imperial College London. Primary endpoint: Change in hepatic immune cell counts. Started Apr 2018; status: completed.
02
Drugs
maraviroc
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN15410818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15410818.